Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder (URIS-1)
Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder: A Prospective, Randomized, Sham-Controlled Clinical Trial
This prospective, randomized, sham-controlled clinical investigation evaluates the efficacy and safety of peroneal transcutaneous electrical neuromodulation (URIS I system) in children aged 7-12 years with wet overactive bladder and daytime urinary incontinence who did not respond or responded insufficiently to standard urotherapy. Participants are randomized 1:1 to active or sham stimulation and receive 12 weekly bilateral sessions of 30 minutes over 12 weeks.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Investigator-initiated academic study sponsored by the General University Hospital in Prague. The primary objective is to determine the effect of peroneal transcutaneous electrical neuromodulation on the frequency of daytime urinary incontinence in children with overactive bladder. The primary variable is the clinical responder rate at the end of treatment (week 12). Secondary objectives are the effect on micturition frequency, functional bladder capacity, parent- and child-reported symptoms and quality of life (DVISS, PIN-Q, PGI-I), clinician-rated global improvement (CGI-I), and the safety, tolerability and adherence to treatment.
Children are randomized 1:1 (permuted blocks, sealed opaque envelopes) to active stimulation or sham stimulation with the stimulation voltage set to 0 V. Both procedures are identical in preparation, electrode placement, duration and the 4 Hz acoustic signal; the child and the parent are separated from the lower limbs by an opaque screen. Planned sample size: 21 evaluable participants per arm; 47 participants are to be enrolled to allow for approximately 10% attrition.
The URIS I device is supplied by the manufacturer, Stimvia s.r.o., under a loan agreement. The manufacturer is not a sponsor or collaborator of this study.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Zuzana Jiraskova, MD, FEAPU
- Phone Number: +420 224 967 859
- Email: zuzana.jiraskova@vfn.cz
Study Contact Backup
- Name: Petra Novakova, MD
- Phone Number: +420 224 967 859
- Email: petra.novakova@vfn.cz
Study Locations
-
-
-
Prague, Czechia, 128 08
- Recruiting
- General University Hospital
-
Contact:
- Zuzana Jiraskova, MD, FEAPU
- Phone Number: +420 224 967 859
- Email: zuzana.jiraskova@vfn.cz
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children aged 7 to 12 years, boys and girls
- Wet form of overactive bladder (urgency with daytime urinary incontinence, with or without nocturnal enuresis)
- At least 8 wet days during waking hours in 2 weeks, based on the wetting diary
- No or insufficient response to standard urotherapy (ICCS) lasting at least 3 months
- Ability and willingness of the child and the parent to follow the protocol; signed informed consent
Exclusion Criteria:
- Severe daytime incontinence (complete wetting in more than 50% of episodes)
- Anticholinergic treatment for overactive bladder in the last 3 months
- Neurogenic lower urinary tract dysfunction
- Congenital malformations of the lower urinary tract (e.g. bladder exstrophy, anorectal malformation)
- Severe systemic or neurological disease (e.g. cardiac disorders, epilepsy)
- Local lesions of the lower limbs (skin disease, osteosynthesis material)
- Peripheral neuropathy of the lower limbs
- Presence of an electronic implant in the body (e.g., a neurostimulator)
- Functional constipation during the previous 3 months (Rome III-IV criteria)
- Symptomatic urinary tract infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Active stimulation
Active bilateral peroneal transcutaneous neuromodulation with URIS I, 30 minutes, once a week for 12 weeks. |
Bilateral peroneal transcutaneous electrical neuromodulation with the URIS I system. A neutral self-adhesive electrode is placed on the lower abdomen; the optimal stimulation point at the lateral edge of the popliteal fossa is identified by a rhythmic motor response of the leg, and the stimulation voltage is set to the lowest value that evokes this response. Stimulation lasts 30 minutes, once a week for 12 weeks (12 sessions). The device emits a 4 Hz acoustic signal. |
|
Sham Comparator: Sham stimulation
Sham stimulation with URIS I at 0 V (no stimulation delivered), same procedure, electrode placement, 4 Hz acoustic signal and schedule as the active arm: 30 minutes, once a week for 12 weeks. |
Identical preparation, electrode placement and duration as active stimulation, but the stimulation voltage is set to 0 V bilaterally so that no stimulation is delivered. Exposure to active stimulation is limited to the minimum needed to locate the stimulation point. 30 minutes, once a week for 12 weeks (12 sessions). The device emits the same 4 Hz acoustic signal. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of clinical responders at the end of treatment
Time Frame: Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)
|
A clinical responder is a child who meets either or both of the following criteria at the end of treatment:
|
Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the number of daytime incontinence episodes per 24 hours
Time Frame: Baseline, Week 6, Week 12
|
Number of incontinence episodes during waking hours per 24 hours, averaged over 14 days of the wetting diary; change from baseline. |
Baseline, Week 6, Week 12
|
|
Change in the severity of daytime incontinence episodes
Time Frame: Baseline, Week 6, Week 12
|
Severity of incontinence episodes (complete vs. partial wetting) per 24 hours during waking hours over 14 days of the wetting diary; change from baseline. |
Baseline, Week 6, Week 12
|
|
Change in the number of wet days
Time Frame: Baseline, Week 6, Week 12
|
Number of wet days during waking hours over 2 weeks (a wet day is a day with leakage producing a stain on underwear larger than a 10 CZK coin / 1 EUR coin); change from baseline. |
Baseline, Week 6, Week 12
|
|
Change in micturition frequency and functional bladder capacity
Time Frame: Baseline, Week 6, Week 12
|
Mean number of voids per 24 hours and mean voided volume (functional bladder capacity) from the 48-hour frequency-volume chart; change from baseline. |
Baseline, Week 6, Week 12
|
|
Change in DVISS total score (parent-rated)
Time Frame: Baseline, Week 6, Week 12
|
Dysfunctional Voiding and Incontinence Symptom Score total score completed by the parent; change from baseline. Higher scores indicate more severe symptoms. |
Baseline, Week 6, Week 12
|
|
Change in Bower PIN-Q total score (child-rated)
Time Frame: Baseline, Week 6, Week 12
|
Pediatric Incontinence Questionnaire (PIN-Q) total score completed by the child as a measure of quality of life; change from baseline. |
Baseline, Week 6, Week 12
|
|
PGI-I score rated by the child and by the parent
Time Frame: Week 6, Week 12
|
Patient Global Impression of Improvement, rated separately by the child and by the parent (1 = very much better to 7 = very much worse). |
Week 6, Week 12
|
|
CGI-I score rated by the unblinded investigator
Time Frame: Week 6, Week 12
|
Clinical Global Impression of Improvement rated by the principal investigator or co-investigator (1 = very much improved to 7 = very much worse). |
Week 6, Week 12
|
|
Number, type and severity of treatment-related adverse events
Time Frame: From the first stimulation to Week 12
|
Adverse events (description, severity, onset, resolution, action taken and relationship to neuromodulation) recorded at every stimulation session and visit. |
From the first stimulation to Week 12
|
|
Adherence to treatment
Time Frame: Week 12
|
Proportion of participants who attend at least 80% of the 12 planned stimulation sessions. |
Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Zuzana Jiraskova, MD, FEAPU, General University Hospital, Prague
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Mental Disorders
- Male Urogenital Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urination Disorders
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Behavioral Symptoms
- Elimination Disorders
- Urinary Bladder Diseases
- Pathological Conditions, Signs and Symptoms
- Behavior
- Signs and Symptoms
- Enuresis
- Urinary Bladder, Overactive
- Diurnal Enuresis
Other Study ID Numbers
Other Study ID Numbers
- Uris_01_2026
- 000058 (Other Identifier: ISZP)
- sukls114680/2026 (Other Identifier: State Institute for Drug Control (SUKL))
- sukl222573/2026 (Other Identifier: State Institute for Drug Control (SUKL))
- 376/26 A, IB, D, PS (Other Identifier: Ethics Committee, General University Hospital in Prague)
- 443/26 A, IB (Other Identifier: Ethics Committee, General University Hospital in Prague)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data (IPD) will not be shared to protect patient privacy, as this study evaluates a vulnerable pediatric population and is subject to strict GDPR and institutional data protection regulations.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.